Why investors are taking another look at kidney disease
From BioSpace · · 18 min
This plays from the publisher's own server. We do not host a copy.
Description
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.
Host
Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace
Guests
Bruce Culleton (https://www.linkedin.com/in/bruce-culleton-424b827/), CEO, ProKidney
Demetri Maxim (https://www.linkedin.com/in/demetri-maxim/), CEO, Nephrogen
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.